Biomarkers of phenotype, prognosis and response to therapy in pancreatic cancer.

胰腺癌表型、预后和治疗反应的生物标志物。

• 批准号: nhmrc : 535994
• 负责人: Dr David Chang
• 金额: $ 7.06万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/biomarkers-phenotype-prognosis-pancreatic-cancer/115856
• 关键词: Biomarkers; phenotype; prognosis; response; therapy

Pancreatic cancer (PC) is the 4th leading cause of cancer deaths in our society. This research is aimed at the discovery of novel biomarkers with the ability to forecast prognosis and response to treatments in patients with PC. Ultimately, this will lead to the “individualisation” of the treatment for each patient, so that the most appropriate therapy could be given to an individual patient. This would significantly improve the overall survival and the quality of life for patients.

胰腺癌（PC）是我们社会癌症死亡的第四大原因。这项研究旨在发现能够预测 PC 患者预后和治疗反应的新型生物标志物。最终，这将导致每个患者的治疗“个体化”，以便为每位患者提供最合适的治疗。这将显着提高患者的总体生存率和生活质量。